Want to join the conversation?
$CELG's sales from Otezla for 3Q15 increased by $121.1MM from last year, reflecting net sales of $128.4MM in the U.S. and $10.3MM in international markets. Sales from Abraxane rose by 8.3%, primarily due to increased unit volumes in international markets.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?